. . . "Oxibendazolo"@en . . "# Gokbulut C, Nolan AM, McKellar QA: Plasma disposition, faecal excretion and in vitro metabolism of oxibendazole following oral administration in horses. Res Vet Sci. 2002 Feb;72(1):11-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12002632 # Magambo JK: Ultrastructural changes in Ascaris suum after oxibendazole treatment. Afr J Health Sci. 1998 Feb;5(1):38-41. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17580993"@en . . "Oxibendazole is a polymerase inhibitor in phase III trials for the treatment of helminth intestinal infections."@en . . "20559-55-1"@en . . . . . . . . " "@en . . . . . "Methyl (5-propoxy-1H-benzimidazol-2-yl)carbamate"@en . . "Oxybendazole"@en . "OBZ"@en . . . "Oxibendazole causes degenerative alterations in the tegument and intestinal cells of the worm by binding to the colchicine-sensitive site of tubulin, thus inhibiting its polymerization or assembly into microtubules. The loss of the cytoplasmic microtubules leads to impaired uptake of glucose by the larval and adult stages of the susceptible parasites, and depletes their glycogen stores. Degenerative changes in the endoplasmic reticulum, the mitochondria of the germinal layer, and the subsequent release of lysosomes result in decreased production of adenosine triphosphate (ATP), which is the energy required for the survival of the helminth. Due to diminished energy production, the parasite is immobilized and eventually dies."@en . . . "(5-Propoxy-1H-benzimidazol-2-yl)carbamic acid methyl ester"@en . . "Oxibendazole"@en . "methyl 5-[n-propoxy]benzimidazole-2-carbamate"@en . "Oxibendazolum"@en . "5-Propoxy-2-benzimidazolecarbamic acid methyl ester"@en . . "Methyl 5-n-propoxy-2-benzimidazole carbamate"@en . "Helminthic Microorganisms"@en . . . . . . "investigational"@en . "Investigated for use/treatment in infectious and parasitic disease (unspecified) and pediatric indications."@en . . . . . "Methyl 5-propoxy-2-benzimidazolecarbamate"@en . .